https://www.selleckchem.com/products/c381.html
Potential key mechanisms that may explain the notable cardioprotective benefits of SGLT2 inhibitors have been outlined. These agents have recently received class Ia recommendation in specific groups of people with DM to lower the risk of hospitalization for HF and risk of death, while these benefits may also extend to people without diabetes. It remains to be seen whether they will also emerge as treatment approaches in the acute phase of CV episodes. Potential key mechanisms that may explain the notable cardioprotective benefits of SGLT2
Like
Comment
Share
